Acute myelomonocytic leukemia in a horse.

Veterinarians describe a 7-year-old Quarter Horse that developed acute myelomonocytic leukemia months after showing persistent low white blood cells and platelets following colic surgery; low-dose cytosine arabinoside treatment was ineffective, and widespread organ infiltration was found at necropsy. The early blood count abnormalities likely reflected a preleukemic, dysplastic phase before overt leukemia.

What this paper reports and why it matters

• Describes a single-horse case of acute myelomonocytic leukemia (AMML), a rare hematologic cancer in equids involving both granulocytic and monocytic cell lines.
• Highlights that persistent leukopenia and thrombocytopenia preceded overt leukemia, suggesting a myelodysplastic or preleukemic phase that could offer an earlier diagnostic window.
• Documents systemic organ infiltration and unsuccessful treatment with low-dose cytosine arabinoside (cytarabine), underscoring the guarded prognosis and therapeutic challenges in horses.

Case timeline and key clinical findings

• Initial presentation: A 7-year-old Quarter Horse stallion with a pre-existing myeloproliferative disorder developed colic; surgery revealed and removed an enterolith.
• Postoperative course: Secondary complications occurred, and bloodwork identified leukopenia (low white blood cells) and thrombocytopenia (low platelets).
• Five-month interval: The horse re-presented with recurrent peripheral edema and an abdominal incisional hernia requiring repair.
• Diagnosis at that time: Acute myelomonocytic leukemia was diagnosed based on hematologic evaluation (details not provided in the abstract but consistent with acute myeloid leukemia affecting myeloid and monocytic lineages).
• Treatment attempt: Low-dose, noncytocidal cytosine arabinoside was administered but was unsuccessful.
• Outcome: The horse died/euthanasia ensued; necropsy revealed widespread neoplastic infiltration.

Pathophysiology and diagnostic considerations for AMML

• Definition: AMML is a subtype of acute myeloid leukemia characterized by proliferation of blasts with both granulocytic and monocytic differentiation (analogous to FAB M4 in human classification).
• Clinical biology: Rapid expansion of immature myeloid cells replaces normal marrow, leading to cytopenias (e.g., anemia, leukopenia or dysfunctional leukocytosis, thrombocytopenia) and extramedullary infiltration of organs.
• Typical diagnostics (not detailed in the abstract but standard for AMML):
  • Complete blood count and smear: blasts, dysplastic changes; cytopenias common.
  • Bone marrow aspirate/biopsy: increased blasts with dual myeloid/monocytic features.
  • Cytochemical stains and/or immunophenotyping: myeloperoxidase and nonspecific esterase positivity supporting mixed-lineage differentiation.
• Relevance to this case: Persistent leukopenia and thrombocytopenia before overt leukemia suggest early marrow failure from dysplasia, with later transition to frank AMML.

Clinical signs and complications explained

• Leukopenia: Increases infection risk and can follow marrow suppression from dysplasia or early leukemic infiltration.
• Thrombocytopenia: Predisposes to bleeding; complicates surgery and recovery.
• Peripheral edema (months later): Likely multifactorial—possible hypoproteinemia from chronic disease, venous/lymphatic compromise, or capillary leak associated with systemic inflammation or leukemic infiltration.
• Incisional hernia: A known postoperative complication; impaired wound healing may be exacerbated by cytopenias and systemic illness.

Treatment attempted and rationale

• Agent: Cytosine arabinoside (cytarabine), an antimetabolite that inhibits DNA synthesis, commonly used for myeloid leukemias.
• Dosing strategy: “Low-dose, noncytocidal” approach aimed to modulate leukemic proliferation while minimizing further marrow suppression—important in a large animal with existing cytopenias.
• Outcome: Therapy was ineffective in this case, consistent with the generally poor response of equine acute leukemias to conventional chemotherapy and the challenges of delivering intensive regimens in horses.
• Implication: Supportive care alone is often insufficient; effective, tolerated chemotherapy protocols for equids remain limited.

Necropsy findings and their significance

• Organs involved: Spleen, liver, lung, adrenal gland, testes, and eye showed leukemic (neoplastic) infiltrates.
• Interpretation: Confirms systemic dissemination beyond bone marrow (extramedullary leukemia), explaining diverse clinical signs and refractory disease.
• Notable sites:
  • Ocular involvement can cause vision changes and ocular inflammation.
  • Adrenal infiltration may contribute to systemic illness via endocrine or hemodynamic effects.

Preleukemia and hematopoietic dysplasia in context

• Concept: Myelodysplastic syndromes (hematopoietic dysplasia) are clonal marrow disorders with ineffective hematopoiesis leading to cytopenias and risk of progression to acute leukemia.
• Evidence here: Months of persistent leukopenia and thrombocytopenia before overt AMML support a dysplastic or preleukemic phase.
• Clinical takeaway: Unexplained, sustained cytopenias in horses warrant thorough evaluation (including marrow assessment) because they may precede acute leukemia.

Strengths, limitations, and implications

• Strengths: Detailed clinical course linked to necropsy provides clinicopathologic correlation of equine AMML with systemic infiltration.
• Limitations: Single-case report; limited diagnostic detail (e.g., cytochemistry/immunophenotyping not specified); therapy details sparse; generalizability is constrained.
• Practice implications:
  • Maintain high suspicion for marrow disease in horses with persistent cytopenias, especially postoperatively or with unexplained edema.
  • Early referral for hematologic workup, including bone marrow examination, may identify preleukemic states.
  • Prognosis for equine acute myeloid leukemias remains poor; client counseling should reflect limited therapeutic success.

Key takeaways for veterinarians

• Persistent leukopenia and thrombocytopenia can herald progression to acute leukemia in horses.
• AMML may present with systemic signs and organ infiltration; diagnosis typically requires marrow analysis and lineage confirmation.
• Current chemotherapeutic options, including low-dose cytarabine, often fail to control disease in equids; prognosis is guarded to poor.
• Postmortem findings validate the aggressive, disseminated nature of equine AMML and emphasize the need for earlier detection and better treatments.